Month: May 2020

Resistance of Synthetic and Biologic Surgical Meshes to Methicillin-Resistant Staphylococcus aureus Biofilm: An In Vitro Investigation.

Resistance of Synthetic and Biologic Surgical Meshes to Methicillin-Resistant Staphylococcus aureus Biofilm: An In Vitro Investigation.

Surgical meshes have develop into the usual process for a spread of surgical purposes with 20 million meshes being implanted every year. The reputation of mesh utilization amongst surgeons is backed by the a number of research that assist its performance as a software for bettering surgical outcomes. However, their use has additionally been related …

Resistance of Synthetic and Biologic Surgical Meshes to Methicillin-Resistant Staphylococcus aureus Biofilm: An In Vitro Investigation. Read More »

Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study.

Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study.

To assess the dangers of malignancies, infections and autoimmune ailments in patients with rheumatoid arthritis (RA) handled with abatacept compared with other biologic (b) disease-modifying antirheumatic drugs (DMARDs) or conventional synthetic (cs)DMARDs, in a US-wide observational RA cohort METHODS: Data have been reviewed from patients (≥ 18 years) with RA who have been registered with …

Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study. Read More »

Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting.

Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting.

To assess incidence charges (IRs) of VTE in patients with rheumatoid arthritis (RA) on completely different DMARDs and DMARD switchers.Adults with RA on a DMARD between 2007 and 2017 have been studied in a US claims database. Conventional synthetic DMARD (csDMARD) customers, first biologic/targeted synthetic DMARD (b/tsDMARD) customers and b/tsDMARD switchers (from a b/tsDMARD to …

Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting. Read More »

Scroll to Top